These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 20229247)

  • 21. Differences in the atherogenic risk of patients treated by lipoprotein apheresis according to their lipid pattern.
    von Dryander M; Fischer S; Passauer J; Müller G; Bornstein SR; Julius U
    Atheroscler Suppl; 2013 Jan; 14(1):39-44. PubMed ID: 23357139
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Review: the oxidant/antioxidant balance during regular low density lipoprotein apheresis.
    Schettler V; Methe H; Staschinsky D; Schuff-Werner P; Müller GA; Wieland E
    Ther Apher; 1999 Aug; 3(3):219-26. PubMed ID: 10427619
    [TBL] [Abstract][Full Text] [Related]  

  • 23. LDL apheresis: a novel technique (LIPOCOLLECT 200).
    Stefanutti C; Di Giacomo S; Mazzarella B; Castelli A
    Artif Organs; 2009 Dec; 33(12):1103-8. PubMed ID: 19995360
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-term efficacy of low-density lipoprotein apheresis for focal and segmental glomerulosclerosis.
    Kawasaki Y; Suzuki S; Matsumoto A; Takano K; Suyama K; Hashimoto K; Suzuki J; Suzuki H; Hosoya M
    Pediatr Nephrol; 2007 Jun; 22(6):889-92. PubMed ID: 17277952
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lipoprotein apheresis.
    Moriarty PM; Hemphill L
    Cardiol Clin; 2015 May; 33(2):197-208. PubMed ID: 25939293
    [TBL] [Abstract][Full Text] [Related]  

  • 26. N-acetylcysteine inhibits in vivo oxidation of native low-density lipoprotein.
    Cui Y; Narasimhulu CA; Liu L; Zhang Q; Liu PZ; Li X; Xiao Y; Zhang J; Hao H; Xie X; He G; Cui L; Parthasarathy S; Liu Z
    Sci Rep; 2015 Nov; 5():16339. PubMed ID: 26536834
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The lipid- and lipoprotein- [LDL-Lp(a)] apheresis techniques. Updating.
    Stefanutti C; Morozzi C; Perrone G; Di Giacomo S; Vivenzio A; D'Alessandri G
    G Chir; 2012; 33(11-12):444-9. PubMed ID: 23140934
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Direct adsorption of low-density lipoprotein by DALI-LDL-apheresis: results of a prospective long-term multicenter follow-up covering 12,291 sessions.
    Bosch T; Gahr S; Belschner U; Schaefer C; Lennertz A; Rammo J;
    Ther Apher Dial; 2006 Jun; 10(3):210-8. PubMed ID: 16817783
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Red grape seed extract improves lipid profiles and decreases oxidized low-density lipoprotein in patients with mild hyperlipidemia.
    Razavi SM; Gholamin S; Eskandari A; Mohsenian N; Ghorbanihaghjo A; Delazar A; Rashtchizadeh N; Keshtkar-Jahromi M; Argani H
    J Med Food; 2013 Mar; 16(3):255-8. PubMed ID: 23437789
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Improved neuronal survival of focal ischemia after delipid extracorporeal lipoprotein treatment in hyperlipidemic rabbits.
    Liu G; Wang W; Xie H; Che Y; Xue J; Wu Y; Zhou Q; Kong D
    Artif Organs; 2011 Jul; 35(7):E145-54. PubMed ID: 21749409
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The first case report of the treatment of transplant coronary artery disease with dextran sulfate adsorption lipid apheresis.
    Sosland RP; Gollub SB; Wilson DB; Moriarty PM
    Ther Apher Dial; 2010 Apr; 14(2):218-21. PubMed ID: 20438545
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Direct adsorption of low-density lipoprotein and lipoprotein(a) from whole blood: results of the first clinical long-term multicenter study using DALI apheresis.
    Bosch T; Lennertz A; Schenzle D; Dräger J;
    J Clin Apher; 2002; 17(4):161-9. PubMed ID: 12494408
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cascade plasma filtration during the first year after CABG in patients with hyperlipidemia refractory to statins.
    Ezhov MV; Il'ina LN; Safarova MS; Afanasieva OI; Adamova IY; Atanesyan RV; Konovalov GA; Akchurin RS; Pokrovsky SN
    Atheroscler Suppl; 2013 Jan; 14(1):101-5. PubMed ID: 23357150
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of low-density lipoprotein apheresis on plasma matrix metalloproteinase-9 and serum tissue inhibitor of metalloproteinase-1 levels in diabetic hemodialysis patients with arteriosclerosis obliterans.
    Nakamura T; Matsuda T; Suzuki Y; Ueda Y; Koide H
    ASAIO J; 2003; 49(4):430-4. PubMed ID: 12918586
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immediate therapeutic efficacy of low-density lipoprotein apheresis for drug-resistant nephrotic syndrome: evidence from the short-term results from the POLARIS Study.
    Muso E; Mune M; Hirano T; Hattori M; Kimura K; Watanabe T; Yokoyama H; Sato H; Uchida S; Wada T; Shoji T; Yuzawa Y; Takemura T; Sugiyama S; Nishizawa Y; Ogahara S; Yorioka N; Sakai S; Ogura Y; Yukawa S; Iino Y; Imai E; Matsuo S; Saito T
    Clin Exp Nephrol; 2015 Jun; 19(3):379-86. PubMed ID: 24934117
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Is lipoprotein (a)-apheresis useful?
    Bambauer R
    Ther Apher Dial; 2005 Apr; 9(2):142-7. PubMed ID: 15828926
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Acute and long-term effects of low-density lipoprotein (LDL)-apheresis on oxidative damage to LDL and reducing capacity of erythrocytes in patients with severe familial hypercholesterolaemia.
    Stefanutti C; Di Giacomo S; Vivenzio A; Isacchi GC; Masella R; Caprari P; Varì R; Tarzia A; Mosiello A; Cantafora A
    Clin Sci (Lond); 2001 Feb; 100(2):191-8. PubMed ID: 11171288
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Changes of autoantibodies against oxidatively modified low density lipoproteins during long-term LDL-apheresis.
    Turk Z; Mrzljak V; Turk N; Metelko Z
    Diabetes Nutr Metab; 1999 Dec; 12(6):413-7. PubMed ID: 10782563
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Compositional lipoprotein changes and low-density lipoprotein susceptibility to oxidation in chronic renal failure patients with heavy proteinuria.
    Karabina SA; Pappas H; Miltiadous G; Bairaktari E; Christides D; Tselepis A; Elisaf M; Siamopoulos K
    Nephron Clin Pract; 2003; 95(3):c77-83. PubMed ID: 14646367
    [TBL] [Abstract][Full Text] [Related]  

  • 40. LDL-apheresis reduces P-Selectin, CRP and fibrinogen -- possible important implications for improving atherosclerosis.
    Kobayashi S; Oka M; Moriya H; Maesato K; Okamoto K; Ohtake T
    Ther Apher Dial; 2006 Jun; 10(3):219-23. PubMed ID: 16817784
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.